Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.57 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750699 | 0.87 | CRHR1 (0.60) | CRHR1NNMTKDM4EMEN1ALDH1A1 | |
| SCHEMBL3753972 | 0.85 | CRHR1 (0.57) | CRHR1NNMTKDM4EMEN1ALDH1A1 | |
| SCHEMBL3751391 | 0.80 | CRHR1 (0.64) | CRHR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL3753893 | 0.80 | CRHR1 (0.62) | CRHR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL16162066 | 0.77 | CRHR1 (0.63) | CRHR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL16162207 | 0.77 | CRHR1 (0.61) | CRHR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL16162068 | 0.77 | CRHR1 (0.61) | CRHR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL3724782 | 0.77 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL16162117 | 0.76 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL3746635 | 0.76 | CRHR1 (0.62) | CRHR1KDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | CRHR1 1/4885NNMT 2499/4885KDM4E 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.